PROGENTEC DIAGNOSTICS, INC.
A multi-analyte diagnostic blood test (Lupus Flare Prediction Index) that measures immune pathway dysregulation to predict SLE disease flares and assess disease activity.
- Sector
- Medtech
- Headquarters
- OKLAHOMA CITY, OK
- Founded
- 2015
- Latest Form D
- $1.3M, Nov 2017
- Total capital
- $3M
- Federal grants
- $1.7M
- 3 awards · 2019–2021
- Rank in peer group#33 of 79
- Private capital raised
- $1.3M
- 1 Form D · last Nov 2017
- 107 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 7 pending · first 2022
- Rank in peer group#19 of 79
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)$743K
- Federal grantHealth and Human S · Phase II · Development of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)$743K
- Federal grantHealth and Human S · Phase II · Development of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)$225K
- Private capital raisedForm D · SEC · 1st filing$1.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 79 peers
Line = medianMedtech · Instrument
- Federal grants#33 · top 42%
- Granted patents#19 · top 24%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mohan PurushothamanResearcherExecutive Officer, DirectorLinked by 1 patent
- Robert SaundersDirectorNamed in SEC Form D filings
- Sanjiv SharmaExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 8- PendingSystems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesUSPTOApplication 18657064
- PendingSystems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesUSPTOApplication 17980864
- GrantedSystems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesUSPTOUS 11,257,579
Show all 8 patent records
- Systems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesNov 14, 2024 · Application 18657064Pending
- Systems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesApr 20, 2023 · Application 17980864Pending
- Systems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesFeb 22, 2022 · US 11,257,579Granted
- Systems And Methods For Managing Autoimmune Conditions, Disorders And DiseasesApplication PCTUS2021030715Pending
- Biomarkers For A Systemic Lupus Erythematosus (sle) Disease Activity Immune Index That Characterizes Disease ActivityApplication PCTUS2024043172Pending
- Artificially Intelligent System And Method For Prognostic Evaluation Of Autoimmune DisordersApplication 19112238Pending
- Artificially Intelligent System And Method For Prognostic Evaluation Of Autoimmune DisordersApplication PCTUS2023033066Pending
- Novel Methods and Systems for Classification of Undiagnosed Persons at Risk of Autoimmune Conditions Using Innovative Virtual and Digital ModelsApplication 63407584Pending
Related companies, and why
- AMAHEALTH LLCSimilar federal contract value in Medtech · null in contracts
- NFlection Therapeutics, Inc.Similar federal contract value in Medtech · null in contracts
- CALYX, INC.Similar federal contract value in Medtech · null in contracts
- Orthios Innovations LLCSimilar federal contract value in Medtech · null in contracts
- FreenomeSimilar federal contract value in Medtech · null in contracts
- BioRegenx Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .